1. Home
  2. NVAWW vs WGSWW Comparison

NVAWW vs WGSWW Comparison

Compare NVAWW & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nova Minerals Limited Warrant

NVAWW

Nova Minerals Limited Warrant

HOLD

Current Price

$31.40

Market Cap

0.0

Sector

N/A

ML Signal

HOLD

Logo GeneDx Holdings Corp.

WGSWW

GeneDx Holdings Corp.

N/A

Current Price

$0.01

Market Cap

0.0

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
NVAWW
WGSWW
Founded
1987
2017
Country
Australia
United States
Employees
N/A
1300
Industry
Retail: Computer Software & Peripheral Equipment
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NVAWW
WGSWW
Price
$31.40
$0.01
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
729.0
127.6K
Earning Date
03-02-2025
02-18-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$305,450,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
50.79
52 Week Low
$3.50
$0.00
52 Week High
$67.84
$0.13

Technical Indicators

Market Signals
Indicator
NVAWW
WGSWW
Relative Strength Index (RSI) 55.24 45.67
Support Level $23.85 $0.00
Resistance Level $33.23 $0.01
Average True Range (ATR) 1.20 0.00
MACD 0.58 -0.00
Stochastic Oscillator 86.16 36.57

Price Performance

Historical Comparison
NVAWW
WGSWW

About NVAWW Nova Minerals Limited Warrant

Nova Minerals Ltd is a Gold, Antimony and Critical Minerals exploration and development company focused on advancing the Estelle Project. It includes projects such as Estelle Gold and Critical Minerals Project, RPM, Korbel, Train and Stoney. It operates in one segment which is exploration of minerals and two geographical areas, being Australia and United States, where Australia derives maximum revenue.

About WGSWW GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: